Skip to main content
NKMAX Co., Ltd. logo

NKMAX Co., Ltd. — Investor Relations & Filings

Ticker · 182400 ISIN · KR7182400002 KO Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2025-06-19 Legal Proceedings Report
Country KR South Korea
Listing KO 182400

About NKMAX Co., Ltd.

https://nkmax.com/

NKMAX Co., Ltd. is a biotechnology company focused on developing immune-based solutions centered on Natural Killer (NK) cells. The company's primary focus is the development of adoptive cell therapies to treat incurable diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. Its portfolio includes anti-cancer immunotherapy treatments and other biological products. In addition to therapeutics, NKMAX develops and markets a precision diagnostic test that measures NK cell activity. The company also manufactures and supplies specialized reagents, such as high-quality recombinant proteins and antibodies, for biotechnology research, as well as a line of health functional foods designed to support the immune system.

Recent filings

Filing Released Lang Actions
회생계획인가
Legal Proceedings Report Classification · 100% confidence The document is an official regulatory filing from the Seoul Rehabilitation Court regarding the approval of a rehabilitation plan for NKMAX. It details the court's decision, the rehabilitation plan's contents (debt repayment, debt-to-equity swaps, and capital changes), and references previous related disclosures. Since this is a formal regulatory announcement of a court-ordered corporate restructuring and rehabilitation plan, it falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A or Share Issue alone, but rather represents a comprehensive regulatory update on the company's legal status.
2025-06-19 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange) regarding a decision for a third-party capital increase (유상증자결정) as part of a court-approved rehabilitation plan (회생계획). This document details the issuance of new shares for debt-to-equity conversion. Under the provided filing categories, this falls under 'Share Issue/Capital Change' (SHA) as it specifically details the issuance of new shares and capital structure changes.
2025-06-19 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from NKMAX regarding the results of a securities issuance (specifically a third-party allocation capital increase via debt-to-equity swap following a court-approved rehabilitation plan). This falls under the category of share issuance and capital changes, as it details the actual issuance of new shares.
2025-06-19 Korean
주요사항보고서(감자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korea Exchange regarding a capital reduction (감자 결정) for NKMAX Co., Ltd. This filing details specific corporate actions related to capital structure changes, including stock consolidation and debt-to-equity swaps under a court-approved rehabilitation plan. Since this document describes a significant change in capital structure and share issuance/cancellation, it falls under the 'Share Issue/Capital Change' category.
2025-06-19 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Korea Exchange (KRX) regarding a decision for a third-party paid-in capital increase (유상증자결정). This is a formal regulatory filing detailing capital structure changes, specifically the issuance of new shares as part of a corporate rehabilitation plan. Under the provided classification schema, announcements regarding new share issues or capital changes are classified as 'SHA'.
2025-06-19 Korean
최대주주변경
Major Shareholding Notification Classification · 100% confidence The document is an official regulatory filing from the Korea Exchange (KRX) system regarding a change in the company's largest shareholder (최대주주변경). It details the before-and-after shareholding structure, the reason for the change (debt-to-equity swap due to rehabilitation plan), and the effective date. Since this is a specific regulatory announcement regarding corporate control and shareholding structure that does not fit into the other specific categories like 'Director's Dealing' or 'Major Shareholding Notification' (which usually refer to individual or institutional investors rather than the company's official declaration of a change in control), it is classified as a general regulatory filing.
2025-06-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.